H
Helicore Biopharma
Biopharmaceutical solutions focused on discovering and developing weight-loss therapeutics
About Helicore Biopharma
Helicore Biopharma, Inc. is a biopharmaceutical company at the forefront of developing novel weight loss therapeutics. The company is focused on the discovery and advancement of innovative treatments for obesity, primarily through its lead candidate, HCR 188. This first-in-class biologic GIP antagonist offers a differentiated mechanism of action, targeting the elevation of nutrient-stimulated glucose-dependent insulinotropic polypeptide (GIP) levels. By directly binding to the hormone, HCR 188 functionally neutralizes active GIP in circulation, aiming to reverse the physiological underpinnings of obesity. Helicore's approach seeks to mitigate the chronic effects of dysregulated GIP signaling, which can lead to glucose intolerance and insulin resistance, ultimately driving obesity. The company operates in the biopharmaceutical market, serving healthcare providers and patients seeking effective weight loss solutions. Helicore's business model involves advancing its therapeutic candidates through clinical trials, with plans to enter the clinic by early 2025. Revenue generation is anticipated through successful commercialization of its therapies post-clinical validation. The company recently secured $65 million in Series A financing, underscoring investor confidence in its potential to address significant unmet needs in obesity treatment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 58.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Medical Research, Weight Management, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jan 2025 | $65M | $260M | Longitude Capital · Wellington Management · OrbiMed · Versant Ventures | ↗ |
Growth signals
Latest recorded traffic for Helicore Biopharma is 260 monthly website visits, down 90.7% over the last three months. Helicore Biopharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Helicore Biopharma in the San Mateo ecosystem
The Helicore Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
OrbiMed
Versant Ventures
Longitude Capital
Wellington Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Helicore Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Helicore Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










